For the first time since late 2001, the U.S. stock market has emerged as the most preferred market by global equities fund managers, according to a recent Merrill Lynch survey. WealthTrack will debate the merits of U.S. vs. foreign stocks with star money manager Bill Wilby, the former long time portfolio manager of Oppenheimer’s Global Fund and Merrill Lynch’s emerging market equities strategist, Michael Hartnett. Treasury bond guru Robert Kessler will discuss the fixed income outlook for the rest of the year.
Bill Wilby
Private Investor Oppenheimer Global Fund
“The
One Investment...”
Premier Bio-Tech
- Genentech, Inc. (DNA)
Price: $67.24 on 5/2
52-week range: $65.35 - $82.50
Michael Hartnett
Chief Global Emerging Market Equities Strategist Merrill Lynch
This WealthTrack transcript
is available for just $4.99. You can purchase and
download it safely and securely with your credit
card or PayPal account. You will need the free Adobe
Acrobat Reader software to view and print the transcipt.
Bill Wilby
Private Investor
